Alexion shares slide on Amgen patent challenge to top-seller

Investors in Alexion Pharmaceuticals are now taking seriously the threat of a legal challenge from Amgen, sending shares down 8% Friday on unexpected news that the U.S. patent office will examine three patents held by the smaller biotech on its top-seller Soliris.